Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
(Thomson Reuters ONE) -
Novartis International AG /
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients
with acute heart failure
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced
cardiovascular death or worsening heart failure in patients with acute heart
failure
* Novartis remains committed to improving and extending the lives of patients
with cardiovascular disease and will continue to invest in ways to improve
their outcomes
Basel, March 22, 2017 - Novartis today announced results from the global Phase
III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of
RLX030 (serelaxin) in patients with acute heart failure (AHF).
RELAX-AHF-2 did not meet its primary endpoints of reduction in cardiovascular
death through Day 180 or reduced worsening heart failure through Day five when
added to standard therapy in patients with AHF.
"We are disappointed this study did not confirm the efficacy of RLX030 in acute
heart failure, especially given the urgent need for effective new treatments for
this condition," said Vas Narasimhan, Global Head, Drug Development and Chief
Medical Officer, Novartis. "We will continue to further analyze the data to
better understand and learn from these results as well as evaluate next steps
for the overall program. Novartis would like to thank the patients,
investigators, and site personnel around the world for their unwavering support
of this study. We remain committed to improving and extending the lives of
patients with cardiovascular disease and will continue to invest in ways to
improve their outcomes."
AHF is a life-threatening medical condition requiring urgent evaluation and
treatment[1], and is the leading cause of hospitalization in those aged over 65
years[2],[3]. Risk of mortality after hospitalization for AHF is high[4]-[11]
with approximately one in five patients not surviving a year afterwards[2],[12]-
[14].
About RELAX-AHF-2
RELAX-AHF-2 (NCT01870778) is an event-driven, multicenter, randomized, double-
blind, placebo-controlled, Phase III trial designed to evaluate the efficacy,
safety and tolerability of RLX030 (serelaxin) when added to standard of care in
patients with acute heart failure (AHF). The study has two primary endpoints;
reduction of cardiovascular (CV) death through Day 180 and occurrence of
worsening heart failure through Day five. The RELAX-AHF-2 study included 6,600
patients hospitalized for AHF and was initiated in October 2013.
About acute heart failure
AHF is a life-threatening condition requiring urgent treatment[1]. An AHF event
may occur as a rapid deterioration of existing heart failure (HF), or may be the
first presentation of HF. The condition is progressive and can be fatal after
patients have one or repeated AHF event(s)[4]. During an AHF event, patients
become severely breathless and need to be rushed to the emergency room for
urgent treatment, making AHF the most common cause of hospitalization in
patients over 65 years[2],[3]. Risk of mortality after hospitalization for AHF
is high[4]-[11] with approximately one in five patients not surviving a year
afterwards[2],[12]-[14].
Despite significant progress in treating other heart conditions (including
chronic HF) there have been no significant treatment breakthroughs that have
improved mortality rates in AHF for decades.
About RLX030
RLX030, a relaxin receptor agonist[15], is a recombinant form of the naturally-
occurring human relaxin-2 hormone. Human relaxin-2 is present in both men and
women and elevated levels in pregnant women are thought to help the body cope
with the additional CV demands during pregnancy[16],[17]
About the Novartis cardiovascular portfolio
Entresto(®) (sacubitril/valsartan) is the first and only approved medicine of
its kind. Entresto has been given a Class I recommendation in United States and
European Union clinical guidelines for treatment of heart failure with reduced
ejection fraction (HFrEF)[18]. Approved indications may vary depending upon the
individual country. Its unique mode of action reduces the strain on the failing
heart by enhancing the protective neuro-hormonal systems (e.g. natriuretic
peptide system) and simultaneously inhibiting the harmful effects of the
overactive renin-angiotensin-aldosterone system (RAAS).
To better understand HF Novartis has established FortiHFy, the largest global
clinical program in HF across the pharmaceutical industry. FortiHFy has more
than 40 active or planned clinical studies designed to extend understanding of
HF as well as to generate an array of additional data on symptom reduction,
efficacy, quality of life benefits and real world evidence with Entresto.
In addition to CV research in HF, ACZ885 (canakinumab) is currently being
investigated in patients with a previous heart attack and a high degree of
vascular inflammation. The Phase III CANTOS trial is designed to determine if
ACZ885 can reduce the risk of stroke, heart attack or death and is expected to
read out in 2017.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "committed," "will," "next steps," "may," "can," "portfolio,"
"recommendation," "planned," "being investigated," "expected," or similar terms,
or by express or implied discussions regarding potential marketing approvals for
RLX030, potential new indications or labeling for Entresto and ACZ885, or
regarding potential future revenues from RLX030, ACZ885 and Entresto. You should
not place undue reliance on these statements. Such forward-looking statements
are based on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward-looking statements. There can be
no guarantee that RLX030 will be submitted or approved for sale in any market,
or at any particular time. Neither can there be any guarantee that ACZ885 or
Entresto will be submitted or approved for any additional indications or
labeling in any market, or at any particular time. Nor can there be any
guarantee that RLX030, ACZ885 or Entresto will be commercially successful in the
future. In particular, management's expectations regarding RLX030, ACZ885 and
Entresto could be affected by, among other things, the uncertainties inherent in
research and development, including clinical trial results and additional
analysis of existing clinical data; regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure: The Task Force for the diagnosis and treatment
of acute and chronic heart failure of the European Society of Cardiology (ESC).
Eur Heart J. 2016; 37(27):2129-2200.
[2] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke
Statistics-2016 Update: A report from the American Heart Association.
Circulation. 2015; 133:e38-e360.
[3] Weir LM, Pfuntner A, Maeda J, et al. HCUP facts and figures: statistics on
hospital-based care in the United States, 2009. Rockville, MD: Agency for
Healthcare Research and Quality, 2011.
[4] Zannad F, et al. Heart failure burden and therapy. Europace. 2009; 11:v1-v9.
[5] Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart.
2007; 93:1137-46
[6] Tavazzi L, et al. Nationwide survey on acute heart failure in cardiology
ward services in Italy. Eur Heart J. 2006; 27:1207-15.
[7] Garty M, et al. The management, early and one year outcome in hospitalized
patients with heart failure: a national Heart Failure survey in Israel. Isr Med
Assoc J. 2007; 9:227-33
[8] Bui AL, et al. Epidemiology and risk profile of heart failure. Nat Rev
Cardiol 2011; 8(1): 30-41.
[9] Loehr LR, et al. Heart failure incidence and survival (from the
Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101:1016-1022.
[10] Bueno H, et al. Trends in length of stay and short-term outcomes among
Medicare patients hospitalized for heart failure: 1993-2008. JAMA.
2010; 303(21):2141-2147
[11] Gheorghiade M, et al. Systolic blood pressure at admission, clinical
characteristics, and outcomes in patients hospitalized with acute heart failure.
JAMA. 2006; 296:2217-2226.
[12] National heart failure audit: April 2010 - March 2011, NICOR and The
British Society for Heart Failure, commissioned by the Healthcare Quality
Improvement.
[13] O'Connor M, et al. Causes of death and rehospitalization in patients
hospitalized with worsening heart failure and reduced left ventricular ejection
fraction: Results from efficacy of vasopressin antagonism in heart failure
outcome study with tolvaptan (EVEREST) program. American Heart Journal.
2010; 159(5): 842-849.
[14] Hunt S, et al. 2009 focused update incorporated into the ACC/AHA 2005
Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report
of the American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines: developed in collaboration with the International
Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391-e479.
[15] Du X, et al. Cardiovascular effects of relaxin: from basic service to
clinical therapy. Nat. Rev. Cardiol. 2010; 7:48-58.
[16] Teichman S, et al. Relaxin, a pleiotropic vasodilator for the treatment of
heart failure. Heart Fail Rev. 2009; 14:321-329.
[17] Teichman SL, et al. Relaxin: Review of biology and potential role in
treating heart failure. Curr Heart Fail Rep. 2010; 7:75-82.
[18] Based on 2016 ESC HF Guidelines and 2016 ACC/AHA/HFSA Guideline Update.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Agnes Estes
Novartis Global Media Relations Novartis Pharma Communications
+41 61 324 7999 (direct) +41 61 324 0990 (direct)
+41 79 593 4202 (mobile) +41 79 644 1062 (mobile)
eric.althoff(at)novartis.com agnes.estes(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2089606/788912.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 531663
Anzahl Zeichen: 14224
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
